Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
12:54pm, Tuesday, 12'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on be
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
10:46am, Tuesday, 12'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 12'th Aug 2025
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
09:00am, Tuesday, 12'th Aug 2025
NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The
Novo Nordisk Stock: Buy or Sell?
05:00am, Tuesday, 12'th Aug 2025
The company reported quarterly financial results, which have implications for shareholders.
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
04:44am, Tuesday, 12'th Aug 2025
LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk"
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
03:51pm, Monday, 11'th Aug 2025
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profil
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
11:51am, Monday, 11'th Aug 2025
I was right with my Strong Sell rating for Novo Nordisk A/S and the main pillar of my bear case: market share erosion in weight loss treatment. FY 2025 guidance cuts—sales 8–14% CER and operating
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
11:26am, Monday, 11'th Aug 2025
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
Novo Nordisk: Enough Is Enough
10:48am, Monday, 11'th Aug 2025
Novo Nordisk A/S's Q2 earnings disappointed as management issued a cautious growth outlook, but I believe the market overreacted to these headwinds. Despite competition and knock-off products, Novo No
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
10:18am, Monday, 11'th Aug 2025
I invest for long-term total return, prioritizing dividend growth and quality companies trading at bargain valuations, especially during industry downturns. Despite current headwinds like tariffs and
